Setmelanotide in Bardet‐Biedl Syndrome: A 52‐Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort
Fuente:
Wiley Open Access
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Artículo Open Access |
| Published: |
Wiley
2026
|
| Subjects: | |
| Online Access: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1867004665819824128 |
|---|---|
| author | Jesús Argente Andrea M. Haqq Jan Luca Schorfheide Nicolas Touchot Caroline Huber Urs Wiedemann Jeremy Pomeroy |
| author_facet | Jesús Argente Andrea M. Haqq Jan Luca Schorfheide Nicolas Touchot Caroline Huber Urs Wiedemann Jeremy Pomeroy Jesús Argente Andrea M. Haqq Jan Luca Schorfheide Nicolas Touchot Caroline Huber Urs Wiedemann Jeremy Pomeroy |
| collection | Wiley Open Access |
| contents | Setmelanotide in Bardet‐Biedl Syndrome: A 52‐Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort Jesús Argente Andrea M. Haqq Jan Luca Schorfheide Nicolas Touchot Caroline Huber Urs Wiedemann Jeremy Pomeroy Obesity ABSTRACT Objective This analysis aimed to assess the efficacy of setmelanotide over 52 weeks in patients with Bardet‐Biedl syndrome (BBS) compared with an external natural history cohort from the international Clinical Registry Investigating BBS (CRIBBS). Methods Patients with BBS ≥ 6 years of age ( n = 29) treated with setmelanotide for 52 weeks in a phase 3 trial (NCT03746522) and a propensity‐score matched external control cohort ( n = 58) from CRIBBS were included. Responder rate at week 52 was defined as ≥ 0.3‐point decrease in BMI z ‐score (patients ≤ 18 years) or ≥ 10% body weight reduction (adults). Secondary outcomes included changes in BMI, BMI z ‐score, and body weight. Results A significantly greater proportion of patients treated with setmelanotide met the primary endpoint compared with control patients (58.6% vs. 6.9%; p < 0.001). In pediatric patients, 71.4% achieved the primary endpoint vs. 10.7% of controls ( p < 0.001); in adults, corresponding numbers were 46.7% vs. 3.3% ( p = 0.001). Secondary outcomes demonstrated consistent benefits of setmelanotide treatment. Sensitivity analysis using inverse probability of treatment weighting confirmed these findings. Conclusions This indirect comparison provides additional strong evidence that setmelanotide significantly improves weight outcomes in patients with BBS. These findings further support its clinical benefit over 52 weeks in managing obesity associated with BBS. Trial Registration: ClinicalTrials.gov identifier: NCT03746522 10.1002/oby.70125 http://creativecommons.org/licenses/by/4.0/ |
| doi_str_mv | 10.1002/oby.70125 |
| format | Artículo Open Access |
| id | wiley_oa_10_1002_oby_70125 |
| institution | Wiley Open Access |
| license_str_mv | http://creativecommons.org/licenses/by/4.0/ |
| publishDate | 2026 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Setmelanotide in Bardet‐Biedl Syndrome: A 52‐Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort Jesús Argente Andrea M. Haqq Jan Luca Schorfheide Nicolas Touchot Caroline Huber Urs Wiedemann Jeremy Pomeroy Obesity Setmelanotide in Bardet‐Biedl Syndrome: A 52‐Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort Jesús Argente Andrea M. Haqq Jan Luca Schorfheide Nicolas Touchot Caroline Huber Urs Wiedemann Jeremy Pomeroy Obesity ABSTRACT Objective This analysis aimed to assess the efficacy of setmelanotide over 52 weeks in patients with Bardet‐Biedl syndrome (BBS) compared with an external natural history cohort from the international Clinical Registry Investigating BBS (CRIBBS). Methods Patients with BBS ≥ 6 years of age ( n = 29) treated with setmelanotide for 52 weeks in a phase 3 trial (NCT03746522) and a propensity‐score matched external control cohort ( n = 58) from CRIBBS were included. Responder rate at week 52 was defined as ≥ 0.3‐point decrease in BMI z ‐score (patients ≤ 18 years) or ≥ 10% body weight reduction (adults). Secondary outcomes included changes in BMI, BMI z ‐score, and body weight. Results A significantly greater proportion of patients treated with setmelanotide met the primary endpoint compared with control patients (58.6% vs. 6.9%; p < 0.001). In pediatric patients, 71.4% achieved the primary endpoint vs. 10.7% of controls ( p < 0.001); in adults, corresponding numbers were 46.7% vs. 3.3% ( p = 0.001). Secondary outcomes demonstrated consistent benefits of setmelanotide treatment. Sensitivity analysis using inverse probability of treatment weighting confirmed these findings. Conclusions This indirect comparison provides additional strong evidence that setmelanotide significantly improves weight outcomes in patients with BBS. These findings further support its clinical benefit over 52 weeks in managing obesity associated with BBS. Trial Registration: ClinicalTrials.gov identifier: NCT03746522 10.1002/oby.70125 http://creativecommons.org/licenses/by/4.0/ |
| title | Setmelanotide in Bardet‐Biedl Syndrome: A 52‐Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort |
| topic | Obesity |
| url | https://onlinelibrary.wiley.com/doi/10.1002/oby.70125 |